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ABSTRACT 
A major stumbling block encountered in gene therapy clinical trials has been the 
rapid destruction of the therapeutic product by the host's immune response. The goal of this 
work is to diminish the host Cytotoxic T Lymphocyte (CTL) response to gene therapy 
transgenes and transduced cells by incorporating immunosuppression genes into gene therapy 
vectors. The processing and presentation of antigens through the class I Major 
Histocompatibility Complex (class I MHC) pathway is known to be an early response to viral 
infection. Disruption of the class I MHC pathway results in a decrease of the CD8+ CTL 
response and prolongs viral survival in the host. Two viral immune suppression genes that 
interfere with the class I MHC pathway, the herpes virus ICP47 encoding gene and the 
human cytomegalovirus USll gene, were cloned and each incorporated into an LXSN 
retroviral vector. The vectors were used to transduce multiple cell lines including human, 
rat, and dog. The USll gene effectively decreases the class I MHC cell surface expression in 
all cell lines tested whereas the ICP47 gene functions in all but the rat cells. 
cytotoxicity experiments show the level of class I MHC reduction correlates with a reduction 
of specific lysis by anti-tumor primed CTL populations. Three separate applications of 
ICP47 and USll suppression of CTL activity are reported. First, the reduction of class I 
MHC expression in target cells was used to characterize the ability of a clinically relevant 
anti-tumor cell line to select tumor targets. Second, class I MHC cell surface expression was 
reduced in two promising anti-tumor cell lines which are currently being used for allogeneic 
transplant in cancer treatments. Third, USll class I MHC down regulation in murine cells 
was used in an attempt to prolong the survival of a chemically generated tumor model cell 
line m Wvo. 
1 
CHAPTER 1. GENERAL INTRODUCTION 
INTRODUCTION 
The combination of genetic defects being identified and gene target/delivery methods 
being developed has led to an explosion in the number of gene therapy clinical protocols [1]. 
Increasingly, a common problem encountered in gene therapy protocols involves the host's 
immune response to the proteins encoded by the genes inserted [2-4]. The majority of 
protocols utilize viral gene delivery and thus face similar obstacles to those encountered by 
wild type virus [5, 6]. Of the many types of immune responses, the CTL response to class I 
MHC restricted antigens is known to play an early and key role in host response to viral 
infection (Figure 1). As expected, host CTL response to transgenes and viral proteins has 
been observed in viral based gene therapy protocols [7-9]. Viruses have evolved numerous 
mechanisms to circumvent host immune responses [10-12]. Many of these mechanisms 
provide clues that help explain the pathogenesis of these organisms and in turn, suggest 
therapeutic treatments to augment host defenses. Traditionally, this ability of viruses has 
posed significant problems for the treatment of infected individuals. For gene therapy, viral 
evasion of host immune response offers an opportunity to prolong the persistence of 
therapeutic transgenes and the cells they have transduced. 
The earliest specific host response to viral challenge involves the stimulation and 
propagation of CD8* CTL that kill cells presenting viral derived peptides on class I MHC 
molecules (Figure 2). The response involves very specific recognition of short peptides in 
conjunction with the appropriate class I MHC molecule by a CTL possessing the 
corresponding T Cell Receptor (TCR). Genes encoding both class I MHC and TCR are 
polygenic, polymorphic, and expressed co-dominant thereby generating the vast number of 
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peptide presenting and recognizing combinations needed to identify viral protein fragments. 
An individual CTL expresses a single variant of TCR and thus is said to be restricted by its 
corresponding class I MHC/viral peptide complex. The viral peptides are generated from 
viral proteins present in the cytoplasm that are degraded by the proteasome (Figure 3). 
Peptides 8-9 amino acids long are then transported to the endoplasmic reticulum (ER) by the 
Transporter associated with Antigen Processing (TAP) [13, 14], loaded onto an immature 
class I MHC molecule, and sent through the golgi apparatus to be displayed on the cell 
surface. Although all cytoplasmic proteins are subject to this process, CTL recognizing self 
peptides are eliminated in the thymus and thus do not generate a proliferative response. Most 
tissues are susceptible to viral infection and all mammalian tissue types except cornea [15], 
brain [16], and testis [17] present class I MHC antigens on their cell surface. The ubiquitous 
expression of class I MHC, its key role in host response to viral challenge, and recent 
characterization of class I MHC presentation inhibitors are factors making it an attractive 
target for generating gene therapy vectors that defeat this aspect of the immune response. 
Several wild type viruses have evolved means to avoid the class I MHC mediated 
host immune responses. Early in the study of viral pathogenesis it was noted that both 
adenoviruses [18] and members of the Herpes Simplex Virus (HSV) family fail to generate 
CTL responses during portions of their life cycles [19]. Specifically HSV type I and Human 
Cytomegalovirus (HCMV, Human Herpesvirus 5) both fail to stimulate CTL proliferation 
and infected cells present little or no class I MHC on their cell surface. In HSV type I, the 
protein ICP47 has been shown to block transport of peptides from the cytoplasm to the ER by 
blocking the cytoplasmic peptide binding site of the TAP (Figure 3) [20-22]. Without 
peptide, immature class I MHC molecules are retained in the ER and do not get displayed on 
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the cell surface. HCMV uses at least five proteins to interrupt the presentation of class I 
MHC on the cell surface [23]. One of the more effective proteins is encoded by the USl 1 
gene [24,25]. It has been shown to bind mature class I MHC in the ER and rapidly dislocate 
it back into the cytoplasm. In the cytoplasm the class I MHC is degraded and thus does not 
make it to the cell surface. For the work presented herin, both HCMV US 11 and the HSV 
type I gene encoding ICP47 were cloned and incorporated into a murine derived retroviral 
vector system (LXSN) commonly used to deliver therapeutic transgenes in human clinical 
protocols. 
Several gene delivery methods are currently in clinical use to deliver therapeutic 
genes. Each system has advantages and disadvantages that make it suitable for a given task 
(Figure 4). Molony murine leukemia virus (MoMLV) has been the predominant method used 
in clinical trials to introduce therapeutic genes [26, 27]. With a minimal number of genes 
encoded by the vector, host immunological challenge can be minimized. Transduction of 
most mammalian cell types is possible using vector packaged with amphotropic receptor and 
vector integration leads to stable gene expression [28]. For these reasons, LXSN was chosen 
as the vector system to deliver the ICP47 and USll class I MHC suppression genes. The 
drawbacks for use of this system in gene therapy are that LXSN only integrates in dividing 
cells and packaging systems produce low titers relative to other delivery vectors. For m v&ro 
experimentation, the ability to choose rapidly dividing cell lines and select transduced 
populations effectively negates these disadvantages. 
To generate supematants containing viruses encoding ICP47 or USll, a two step 
transduction process was used (Figure 5) [28, 29]. First the LXSN derived vectors were 
transfected into the GP +E86 cell line which contains a stably transduced copy of the 
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necessary GAG, POL, and ENV genes. Only sequence from the LXSN vector contains the 
packaging signal and thus gets assembled into functional virus and secreted into the 
supernatant. The GP +E86 ENV gene encodes an ecotropic envelope protein enabling the 
virus produced from this cell line to transduce other murine cells. This supernatant is then 
used to transduce the PA317 cell line containing an ENV gene that encodes an amphotropic 
envelope protein. Supematants from the PA317 cells were used to transduce the rest of the 
target cells that were discussed herein. This two step process is more efficient at generating 
transduction competent virus containing full-length LXSN sequences. Target cells are then 
selected for in media with G418; a neomycin phosphotransferase homologue that kills cells 
lacking the LXSN encoded Neo* gene. Function of the immune suppression genes was 
assayed using cell surface labeling by an anti-class I MHC Ab, a fluorescent secondary Ab, 
and flow cytometry quantification (Figure 6). 
DISSERTATION ORGANIZATION 
The work presented within this dissertation focuses on the generation of LXSN 
vectors incorporating ICP47 and USll to decrease cell surface presentation of class I MHC 
antigens. In this manner, the suppression of the class I MHC expression and the resulting 
CTL response occurs only in the transduced cells thus avoiding problems associated with 
general immune suppression. Chapter 2 of this dissertation entitled "Effective suppression of 
class I MHC expression by the USll or ICP47 genes can be limited by cell type or IFNy 
exposure" details the construction of vectors and transduction of a panel of cell lines 
representing several tissues. Cell type variability of function by ICP47 and the USll gene 
product and cytokine induction of class I MHC expression are identified as Actors that may 
limit the use of these inhibitors under specific conditions. Chapter 2 has been accepted for 
5 
publication in an upcoming issue of the journal #%%%# Gene 7%erapy. Chapter 3 of this 
dissertation entitled "TALL-104 cytotoxicity correlates with the level of class I MHC 
expression in a nonrestricted manner" makes use of ICP47 and USll inhibition of class I 
MHC expression to characterize the targeting mechanism of the clinically relevant anti-tumor 
cell line TALL-104. Although the work is specific to the TALL-104 cell line, recent 
publications indicate this may involve a novel form of tumor surveillance by a newly 
identified subset of T cells. This chapter will be submitted for publication to the journal 
Cancer jfesearcA. Chapter 4 of this dissertation entitled "Application of class I MHC 
immune suppression for use in allogeneic transplant and tumor model cell evasion of host 
response" reports the results of three groups of experiments designed to exploit the 
advantages of ICP47 and USll within their limitations. The experiments involving 
inhibition of class I MHC presentation in NK-92 cells while maintaining their anti-tumor 
activity will be reformatted and submitted to the journal jd/zfKxzwer jfeaearcA for publication. 
Thomas Radosevich was the principle investigator for the work presented in each 
chapter of this dissertation. Co-major professors Charles J. Link and M. Duane Enger 
advised the work. 
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Figure 1. Review of the cells of the immune system. Non-specific responses such as 
responses to parasites, identification of stressed cells, and non antigen specific secretion 
of cytokines are regulated through basophils, eosinophils, neutrophils, monocytes, and 
NK cells. Humoral responses to specific antigens are mediated by B lymphocytes and 
antigen specific cellular responses are mediated by T lymphocytes. An effective long 
term strategy to evade host detection will likely require means to minimize non specific 
recognition of stressed cells and eliminate antigen specific B cell and T cell mediated 
responses. Figure adapted from 
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Figure 2. A typical time course of various aspects of the immune response. After viral 
infection, non specific responses by cells secreting interferons and other cytokines peak 
within 3-5 days. The first antigen specific response by CTL peaks between 8-12 days 
and leads to the decrease of viral titers. Primary Ab response, likely from antigens 
processed as viral infected cells are killed, peaks around day 15 and the more substantial 
secondary response after additional challenge peaks at 40-45 days. 
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Figure 3. Class I MHC processing and presentation pathway. Cytoplasmic proteins are 
processed into 8-10 AA peptides by the proteasome and transported into the ER. Mature 
class I MHC molecules are assembled and transported through the golgi complex and 
secretory vesicles to the cell surface where they are displayed for recognition by CTL. 
HSV ICP47 and HCMV USll inhibit different steps in the pathway. 
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Figure 4. Advantages and disadvantages of the different gene delivery systems in 
clinical use. 
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Figure 5. Two step process for the generation of virus with amphotropic envelope 
proteins. Plasmid DNA is first transfected into GP +E86 cells where it is reverse 
transcribed, migrates to the nucleus, and stably integrates. GAG, POL, and ENV genes 
are already integrated and function to produce empty viral capsids. The packaging signal 
on the LXSN vectors directs the cell to package full-length retroviral RNA into the 
capsids that are secreted into the supernatant The ecotropic envelope protein encoded by 
the GP +E86 cells enables transduction of other murine cells and the supernatant is used 
to transduce the PA317 cell line. The process is repeated with the exception that the 
PA317 ENV gene encodes an amphotropic receptor enabling the transduction of any 
mammalian cell. 
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Figure 6. Cell surface labeling of class I MHC epitopes. Examples of (A) an attached 
cell line (A375) and (B) a suspension cell line (NK-92) labeled with the H58A Ab. 
H58A recognizes a region of class I MHC that is highly conserved across species. 
Fluorescence is provided by a FITC labeled secondary Ab. Characteristic cell surface 
staining is seen. 
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CHAPTER 2. EFFECTIVE SUPPRESSION OF CLASS I MHC 
EXPRESSION BY THE US11 OR ICP47 GENES CAN BE 
LIMITED BY CELL TYPE OR IFNy EXPOSURE 
A paper accepted by the journal Gene TTzerqpy, 2003 
Thomas J. Radosevich Tatiana Seregina ,^ Charles J. Link ^  
^The Iowa Cancer Research Foundation, Des Moines IA, 
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ABSTRACT 
An impediment encountered in many viral based gene therapy clinical trials has been 
the rapid destruction of the transgene by the hosfs immune response. The processing and 
presentation of antigens through the class I major histocompatibility complex (MHC) 
pathway is the initial specific response to viral infection. Disruption of the class I MHC 
pathway by Herpes Simplex Virus (HSV) or the human Cytomegalovirus (HCMV) results in 
a decrease of the CD8* cytotoxic T lymphocyte (CTL) response and prolongs survival of 
infected cells in the host. Two viral immune suppression genes that interfere with the class I 
MHC presentation pathway, the HSV type IICP47 gene and HCMV US11 gene were cloned 
and each incorporated into a retroviral vector. HSV ICP47 and HCMV US 11 transgenes 
were expressed in multiple cells lines and compared in their abilities to reduce antigen 
presentation on the cell surface by class I MHC. Retroviral supematants were used to 
transduce human, canine, and rat cell lines. FACS analysis of US11 and ICP47 transduced 
cell lines demonstrated substantial reductions in class I MHC cell surface expression in most 
cell lines except in rodent cells where ICP47 is non-functional. The decrease in the level of 
class I MHC expression for ICP47 transduced cell lines ranged from 31% to 98% relative to 
negative controls. US 11 decreased class I cell surface MHC by 67% to 96%. When both 
ICP47 and US 11 are expressed in human cells, a further reduction of class I MHC was 
observed. Next, human A375 melanoma cells were tested to determine if the resulting 
reduction in cell surface class I MHC would reduce m vi/ro cytotoxicity by CTL. A375 cells 
expressing either ICP47 or US 11 demonstrated a two to threefold reduction of specific lysis 
by primed CD8* CTL. These data clearly establish an ability to convey immune protection 
to human cells by viral genes. However, further analysis demonstrated that Interferon 
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gamma (IFNy) could reverse part or all of the down-regulation of class I MHC induced by 
the ICP47 or US 11 genes. The ICP47 and US 11 genes when expressed in target cells 
decrease class I MHC presentation and as such might be employed in strategies to create 
local immunosuppression against transgenes or allografts. 
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OVERVIEW SUMMARY 
Host immune response to vector encoded proteins and therapeutic transgenes is a 
major impediment to attaining long term gene expression in gene therapy applications. 
Several members of the herpes virus family have developed unique strategies for overcoming 
host immune response. ICP47 and the US11 gene products are two viral proteins that inhibit 
presentation of class I MHC on the cell surface. Incorporation of these genes into gene 
transfer vectors may induce local immune suppression by this mechanism. Herein, two 
potential problems with this approach are addressed. First, cell type specific variability of 
function of the viral genes was observed that may limit immune protection for some cell 
types. Secondly, host cytokine release after transgene exposure may upregulate class I MHC 
expression and thus complicate the use of this approach m vfvo. 
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INTRODUCTION 
A common problem encountered in gene therapy protocols involves the host's 
immune response to the proteins encoded by the genes inserted. Transgenes delivered by 
viral vectors face similar host immune surveillance and elimination mechanisms as those 
encountered by wild type virus. The CTL response to class I MHC restricted antigens is 
known to play an early and key role in host response to viral infection. As expected, host 
CTL response to therapeutic transgene proteins and/or viral proteins has been observed in 
gene therapy protocols employing viral vectors to deliver transgenes (Yang ef a/., 1995). 
Host elimination of viral vectors (Lochmuller ef a/., 1996; Riddell ef a/., 1996; Smith ef a/., 
1996), and specific T cell response to a transgene (Poller ef a/., 1996; Tripathy ef a/., 1996) 
have been well documented. Overcoming this host CTL response and prolonging vector 
survival is now recognized as a major goal for many gene therapy models. Optimally, the 
host immune response would be suppressed against only the transduced cells expressing the 
transgene in order to avoid general immune suppression and its complications. 
This work employs two viral genes delivered by a retroviral gene therapy vector to 
reduce class I MHC expression. Several classes of viruses have evolved proteins that 
specifically suppress the CTL response in order to prolong their own survival (Wold and 
Gooding, 1991; Beersma ef a/., 1993; McFadden and Kane, 1994; Fruh ef a/., 1995). Both 
the ICP47 protein and the US11 gene product have been characterized in detail and each 
inhibits a different step in the antigen processing and presentation pathway. ICP47 is a 88 
amino acid immediate early protein that was identified by its ability to block the cell surface 
expression of class I MHC restricted HSV peptides (York ef a/., 1994; Fruh ef a/., 1995). 
The N-terminal 35 amino acids of ICP47 bind to the peptide-binding site on the cytosolic 
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side of the transporter associated with antigen processing (TAP) (Galocha ef a/., 1997). This 
ICP47/TAP association prevents the 8-10 amino acid peptides derived from proteosome 
degraded proteins from entering the endoplasmic reticulum (ER). This leads to the retention 
and degradation of immature class I MHC molecules and reduces their transport through the 
Golgi to the cell surface (Ahn ef a/., 1996; Tomazin ef a/., 1996). The HCMV US11 protein 
aGects a different step in the antigen processing and presentation pathway (Hengel ef a/., 
1996; Wiertz gf a/., 1996). The US11 gene encodes a 215 amino acid transmembrane 
glycoprotein which dislocates the class I MHC heavy chain via a polyubiquitination mediated 
mechanism from the ER to the cytosol where it is rapidly degraded (Kikkert ef a/., 2001; 
Shamu ef a/., 2001). In cells where US11 is expressed, newly synthesized class I MHC 
proteins have a short half-life and are not presented on the cell surface (Beersma ef a/., 
1993). 
The 267 base pair ICP47 and 645 base pair US11 genes can fit easily within the packaging 
constraints of most retroviral gene therapy vectors with additional room for another 
transgene. Their size makes them ideal candidates to suppress immune responses when long 
term gene expression is desired. A direct comparison of ICP47 function to US 11 in multiple 
cell lines was conducted to quantitatively assess reductions of class I MHC expression. In 
varying gene therapy approaches, foreign transgenes have been expressed in a variety of cell 
types and tissues (Cox ef a/., 1993; Engelhardt ef a/., 1993; Bagnis ef a/., 1994; Philip ef a/., 
1994). The ICP47 and US11 genes were evaluated to determine if the strategy can function 
independent of cell type. Our experiments demonstrate significant variability of ICP47 and 
US11 in reducing class I MHC across the human cell lines. In A375 melanoma cells 
reduction of class I MHC on the cell surface after ICP47 or US 11 expression resulted in an 
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expected decrease in specific lysis by CDS* CTL. Although these results are encouraging, 
the immune response is clearly more complex and often involves a host cytokine response 
(Harms and Splitter, 1995; 7hai gf a/., 1996; DeMatteo ef a/., 1999). The potential 
antagonistic effect of the cytokine IFNy was therefore assessed. IFNy has been shown to 
upregulate transcription of genes in the class I MHC locus (Weber and Rosenberg, 1988). 
Culturing cells in IFNy substantially reduces or eliminates the class I MHC decrease induced 
by either ICP47 or US11. This would have the effect of 'unmasking' the transgene in 
response to any local immune challenge that leads to the release of IFNy thus compromising 
long-term immune suppression. Therefore, our data suggests a more complex interplay will 
be required to adapt these immunomodulating genes for application in transgene or transplant 
therapies. 
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MATERIALS AND METHODS 
Vector and cell line construction 
Polymerase chain reaction (PGR) amplification of the ICP47 (Sense: 
GCAAGCTTGAAGCGCGTATGTCGTGGGCCCTGGAAATGGCG, Antisense: 
GCAAGCTTTCAACGGGTTACCGGATTACGGGG ) gene 6om purified HSV DNA 
(Sigma-Aldrich Corp., St. Louis, MO) and the US 11 gene (Sense: 
GCAACGTTGAAGCGCGTATGAACCTTGTAATGCTTATTCTA, Antisense: 
GCAAGCTTTCACCACTGGTCCGAAAACATCCA) Gom HCMV DNA (Sigma-Aldrich 
Corp.) was performed and the products were cloned into the T/A cloning vector PCR 3.1 
(Invitrogen Inc., Carlsbad, CA). Sample clones were sequenced to confirm their identity 
(data not shown). ICP47 and US 11 were excised from PCR3.1 using the restriction 
endonuclease EcoR I and each sub-cloned into the LXSN vector at the EcoR I site(Miller and 
Rosman, 1989). To express US11 from a second vector with a different selection marker, 
US11 was subcloned into the MSCVp vector that employs the puromycin resistance gene. 
The US 11 in MSCVp vector was constructed by excising the Eco RI fragment from the 
PCR3.1 construct and ligating it into the Eco RI site in the multicloning region of the 
MSCVp vector (Clontech Inc. Palo Alto, CA). Vectors in the proper orientation were 
selected (Fig. 1 A, 5A). The LISN, LUSN, US11 in MSCVp, and control LXSN vectors were 
each transfected into the GP+E86 cell line (Hesdorffer ef a/., 1990). Supemalants were 
filtered (0.2pm) and used to transduce PA317 amphotropic vector producer cells (VPC) 
(Miller and Buttimore, 1986). 
The following cell lines were transduced and selected in the neomycin homologue G418 
(lmg/ml) for 2 weeks: A375 human malignant melanoma (Giard ef a/., 1973); SW620 
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human colorectal adenocarcinoma (Fogh ef a/., 1977); A549 human lung carcinoma (Giard gf 
a/., 1973); 293 adenovirus transformed human fetal kidney (Graham gf a/., 1977); IGROV 
human ovarian carcinoma (Benard gf a/., 1985); OVCAR-3 human ovarian adenocarcinoma 
(Hamilton gf a/., 1983); DU 145 human prostate carcinoma (Stone gf a/., 1978); 9L rat brain 
(Lampson gf a/., 1992); D17 dog osteosarcoma (Riggs gf a/., 1974); MOLT-3 human acute 
lymphoblastic leukemia (Minowada gf a/., 1972); VA13 SV40 transformed human fetal 
Gbroblast (Girardi gf a/., 1966). 
Northern analysis 
Total RNA was puriûed 6om the transduced mixed A375 cell lines (RNeasy*, 
Qiagen Inc., Germantown, MD). The RNA was electrophoresed on a 1.2% agarose gel, 
blotted overnight onto nylon membrane (.45 pm) and UV cross-linked. Random primed ^P 
radiolabeled DNA probes were made for the full length ICP47, the full length US11, and a 
680bp fragment of the neomycin phosphotransferase gene. Probes were incubated with the 
membrane for 12 hr at 42° in hybridization solution (Hybrisol* I Hybridization Solution, 
Oncor, Gathersberg, MD) and washed 5 min 2 times in 20x SSC, 1% SDS at room 
temperature. The membrane was then exposed to Kodak XAR-5 film for 30 sec and 
developed. 
Class I MHC Expression assay 
Transduced, mixed populations of cells were briefly trypsinized and labeled with anti-
MHC class I monoclonal Ab H58A (VMRD Inc., Pullman, WA) at 1.5 pg/ml/0.5xl0* cells in 
serum free media at 37° for 1 hr (Davis gf a/., 1987). Cells were washed 5 min in Hank's 
30 
buffer and a 1:64 dilution of goat anti-mouse FTTC labeled secondary Ab (Sigma-Aldrich 
Corp.) in serum free media was added for 30 min at 37°. Cells were again washed 5 min in 
Hank's buffer and resuspended in Phenol red free/serum free media (OptiMEM®, Invitrogen 
Corp., Inc.Grand Island, NY) for fluorescent analysis. All fluorescent analysis experiments 
were performed a minimum of three times and a representative result is shown. Where a 
single peak was observed, the mean fluorescence intensity is reported. The same protocol as 
above was used for the rat cell line with the primary Ab being 0X18 (PharMingen Inc., 
Torry Pines, CA). For IFNy stimulation of class I MHC, cells were cultured 72 hr in media 
containing 400U/ml IFNy with fresh media replacement after the first 48 hr 
Cytotoxicity Assay 
A non-radioactive colorimetric assay was used to determine specific cytotoxicity of 
random donor Peripheral Blood Mononuclear Cells (PBMC) towards vector transduced and 
control target cells. The Cytotox* 96 (Promega Inc., Madison, WI) assay is based on 
measuring lactate dehydrogenase (LDH) release by a reaction with a tetrazolium salt (INT) to 
produce a red fbrmazan product (Korzeniewski and Callewaert, 1983). In briefs target cells 
are plated in a 96 well plate and effector cells are added at the appropriate ratio. After 4 hr, 
supernatant is collected and assayed for LDH content Controls include maximum LDH 
release (detergent lysed), media background, and spontaneous LDH release from both targets 
and effector cells. Data presented is an average from four wells/data point. PMBC were 
isolated from whole blood of a random donor using a sucrose gradient (Ficoll-Paque* Plus, 
Amersham Biosciences, Upsala Sweden) to obtain the buffy coat. Cells were collected and 
expanded seven days in RPMI media plus 10% FBS, MEM sodium Pyruvate, 2-
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Mercaptoethanol, HEPES, MEM non-essential amino acids, and L-Glutamine (Gibco BRL), 
plus 100 units/ml IL2 to stimulate CDS* cell proliferation. CDS* enriched PBMC were 
obtained using a human CD4* cell depletion column (Cytovax Biotechnologies Inc., 
Edmonton, AB, Canada) to remove both CD4* cells and large granular cells. 
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RESULTS 
Expression of ICP47 and/or US11 decreases class I MHC levels on the cell surface of 
transduced cells 
In order to directly compare the function of HSV ICP47 and HCMV US11, both 
genes were cloned into the retroviral vector LXSN (Fig. IA). PA317 based retroviral vector 
producer cell lines were constructed and target cells transduced. Functional transcription of 
the vectors was demonstrated by Northern blot analysis (Fig. IB) in the A375 cell lines 
where all three LXSN derived vectors were shown to functionally transcribe RNA of the 
expected sizes. To detect cell surface class I MHC expression in the A375 cell line, the anti-
class I MHC antibody H58A was used. H58A is a monoclonal Ab raised against a highly 
conserved region of the goat class I MHC heavy chain molecule (Davis gf a/., 1987). It has 
been shown to cross react with class I MHC molecules from multiple species, including all 
human and canine haplotypes tested. A FITC labeled anti-mouse secondary Ab was used to 
detect H58A binding. Characteristic cell surface staining was noted and the results were 
quantified by flow cytometry (Fig. 2A). A single peak was observed and the mean 
fluorescence of the transduced mixed cell population reported (Fig. 2B). In the A375 cell 
line, US 11 decreased class I MHC by 94% as compared to LXSN transduced controls. 
ICP47 reduced cell surface class I MHC by 52%. These results remained consistent over 6 
months in continuous culture (data not shown). 
Down Regulation of class I MHC cell surface expression in multiple human cell lines 
To compare cell line variability of function of ICP47 and US11, both vectors were 
introduced into several human cell lines of different tissue origin and class I MHC expression 
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was quantified (Fig. 3). All human cell lines transduced with the ICP47 and US 11 genes 
showed decreased cell surface expression of class I MHC compared to the LXSN vector 
control. For ICP47, class I MHC cell surface levels dropped over a range of 31% in the 
OVCAR-3 ovarian cancer cells to 98% in the MOLT-3 lymphoma cells (Fig. 3 and 7A). For 
US11, the range of class I MHC cell surface decrease was 64% in VA13 fibroblasts to 96% 
in the MOLT-3 cells. In most cell lines, ICP47 and US11 decreased cell surface class I MHC 
to similar levels. However, in A375 and OVCAR-3 cells ICP47 only reduced class I MHC 
expression to approximately one half that observed with US11. Thus, cell specific 
differences in ICP47 and US11 function are likely to occur. 
Down regulation of claw I MHC cell surface expression in dog and rat cell lines 
ICP47 has minimAl function in rodent cells due to its decreased afGnity for the N-
terminal 45 amino acids of murine TAP (Tomazin gf of., 1996; Tomazin gf oA, 1998). To 
determine if dogs or rats would be appropriate for m vh# studies canine D17 osteosarcoma 
cells and rat 9L gliosarcoma cells were transduced. US11 reduced class I MHC expression in 
both canine D17 and rat 9L cells by 71% and 64% respectively (Fig. 4). The ICP47 gene 
showed similar response in the canine cells to that measured in the human cells lines with a 
87% reduction of class I MHC expression. As expected, ICP47 showed a much lower (24%) 
reduction of the cell surface class I MHC over LXSN control cells than was observed in most 
of the human cell lines. 
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Co-expression of ICP47 and US11 
ICP47 and US11 work at different points in the class I MHC presentation pathway 
and co-expression of the two genes was examined to determine if further decreases could be 
induced. In order to co-express US 11 and ICP47, US11 was cloned into MSCVp, a 
puromycin selectable alternate murine retroviral vector to allow for selection of doubly 
transduced cells (Fig. SA). MSCVp has a mutated 5' LTR containing a murine stem cell 
virus promoter designed to maintain long term expression in embryonic stem cells (Grez ef 
a/., 1990). The MSCVp vector has also been reported to function in other mammalian cells 
(Hawley ef a/., 1994). When compared to the LUSN vector, US11 in MSCVp was 
considerably less effective at reducing cell surface class I MHC. This was demonstrated in 
both A375 and VA13 cells (Fig. 5B, 5C). However, in both cell lines tested, co-expression 
of ICP47 and US11 further decreased the cell surface class I MHC over levels observed with 
either gene alone. 
Decreased specific lysis of transduced target cells by primed PBMC 
Specific lysis of target cells was determined using primed, random donor PBMC or 
CDS* enriched population of primed PBMC. Cytotoxicity results using primed PBMC 
populations follow an expected pattern based upon the class I MHC cell surface expression 
experiments. Both non-transduced and LXSN vector transduced target cells are killed more 
efficiently than LISN or LUSN vector transduced targets (Fig. 6A). When CDS* enriched 
cells are employed these significant differences are more pronounced (Fig. 6B). After CD4* 
depletion, the CDS* enriched population was 82% CDS* (data not shown). At the 10:1 
effectortarget ratio, specific lysis of non-transduced cells was 59%, LXSN transduced 47%, 
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LISN transduced 20%, and LUSN 10%. This confirms that the down regulation of class I 
MHC observed in cells expressing ICP47 and US 11 leads to an wz vz/ro decrease of CTL 
lysis. 
Interferon gamma restores high levels of cell surface expression of MHC I in ICP47 and 
US11 transduced cells 
Molt-3 lymphoma and VA13 Gbroblast cells were cultured in media containing 
400U/ml interferon gamma (IFNy). IFNy is produced by NK cells and subpopulations of T 
cells and is known to upregulate cell surface class I MHC in many cell types. Although both 
ICP47 and US11 virtually eliminated (decreased by 98% and 96% respectively) cell surface 
class I MHC in the Molt-3 cell line, IFNy restored expression to about 35% the amount seen 
in LXSN transduced cells (Fig. 7). In the VA13 cell line, the IFNy effect was even more 
pronounced. Although ICP47 and US11 reduced cell surface class I MHC by 73% and 64% 
respectively, incubation with IFNy increased its expression by greater than 300% in both 
transduced and non-transduced cell lines. Only a minor reduction of cell surface class I 
MHC in the ICP47 and US11 transduced cell lines (4% and 7% respectively) was observed 
after IFNy treatment. 
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DISCUSSION 
Suppression of the immune response only in the transduced cells may aid in 
prolonging transgene survival. ICP47 and US11 decrease expression of class I MHC and the 
corresponding lysis by CTL which is the earliest antigen specific host response to viral 
infection. To assess and compare the use of ICP47 and US 11 for gene therapy purposes, 
both genes were cloned and incorporated into otherwise identical retroviral vectors (Fig. 1 A). 
Transcription of the genes was demonstrated by Northern blot (Fig IB) and function of the 
proteins was indicated by a reduction in cell surface class I MHC in transduced cells (Fig. 2). 
The observed class I MHC reduction correlates with a drop in specific lysis by ei-vzvo 
primed CDS* CTL as expected (Fig. 6). To directly compare function of ICP47 to US11 and 
to determine if tissue specific variabilities present a problem, a panel of human cell lines 
were transduced with both vectors (Fig. 2, 3, and 7). This study identifies and demonstrates 
three potential limits to the application of ICP47 and US 11 for long term therapeutic immune 
suppression. First, the reduced function of ICP47 in two of nine cell lines indicates choice of 
gene used for immune suppression needs to be optimized for each application. Second, the 
range of class I MHC cell surface reduction across cell lines indicates that the choice of 
target cells will be important in determining the successful application of this immune 
suppression. Third, cytokine mediated ^regulation of class I MHC must be circumvented to 
achieve long term transgene expression. 
Comparing ICP47 to US11 within individual cell lines, both genes decreased class I 
MHC to nearly identical levels in seven of the nine human cell lines tested (Fig. 3, 7). These 
results are consistent with a previously published report on ICP47 and US 11 expressed in 
primary human T cells and transformed fibroblasts where both genes decreased class I MHC 
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to similar levels as compared to non-transduced parental cells (Berger gf of., 2000). 
However, in the A375 melanoma and OVCAR-3 ovarian carcinoma cells, ICP47 was less 
than half as effective as US 11 at decreasing class I MHC (Fig. 2, 3). Thus, careful testing of 
these genes in each specific target tissue will be necessary to ensure that adequate class I 
MHC decrease occurs for the given application. 
The question as to what level of m vivo class I MHC decrease is needed to circumvent host 
CDS* CTL response is not easy to address. The antigenicity of specific epitopes and the 
amount of epitope presented are two key factors determining whether or not a CTL response 
occurs. As little as 1 to 200 class I MHC epitopes presented per cell are reported to be 
sufficient to mount a host response (Christinck gf of., 1991; Sykulev gf a/., 1996). 
Antigenicity of specific epitopes varies greatly and with highly antigenic epitopes, less of it 
needs to be presented to initiate CTL mediated killing (Sette gf a/., 1994). Therefore 
depending on the antigenicity of the transgene in question, it may be necessary to achieve 
near complete suppression of class I MHC in order to defeat the CTL response. In the seven 
cell lines where ICP47 and US 11 functioned at comparable levels, the decrease of class I 
MHC ranged from 67% in the SW620 colorectal adenocarcinoma cells to 97% in the MOLT-
3 lymphoblastic leukemia cells (Fig. 3, 7). Our data demonstrates further decreases of class I 
MHC where both genes are co-expressed (Fig. 5) in agreement with previous reports (Berger 
gf a/., 2000). Thus, reducing class I MHC expression to a required level is technically 
feasible using vectors tailored for high expression of the best gene or genes in the given 
target tissue. However, the complete or near complete elimination of class I MHC 
presentation on the cell surface brings a potential new issue to the foreground. Cell surface 
decrease or loss of self class I MHC is one of the known triggers of natural killer (NK) cell 
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mediated killing (Timonen and Helander, 1997). Class I MHC negative cell lines are often 
the model of choice used to demonstrate NK mediated lysis (Yeoman and Robins, 1988). 
Additional strategies might be considered to avoid initiation of NK mediated cell killing such 
as to incorporate an inhibitor of NK mediated lysis into the vector design. HCMV UL18 is a 
distant class I MHC homologue recently shown to protect HCMV infected cells from NK 
mediated lysis (Leong gf of., 1998). UL18 is resistant to US 11 down regulation and thus may 
prove particularly useful in combination with US11 (Park gf aZ., 2002). 
Another potential obstacle to obtaining long term immune suppression by down 
regulation of class I MHC are factors that enhance class I MHC expression and presentation. 
Although partially inhibited by ICP47 and US11, the components of the class I MHC 
processing and presentation pathway are still present and able to function. Many cytokines 
including tumor necrosis factor alpha, IFN-alpha, IFN-beta, IFNy, and others up regulate cell 
surface levels of MHC (Raval gf a/., 1998). IFNy in particular is known to increase cell 
surface class I by increasing transcription of the genes involved via activation of the Jak-
STAT signal transduction pathway (Rosa gf a/., 1983; Darnell gf a/., 1994). IFNy is released 
by several types of lymphocytes in response to immune challenge, and thus the ability of 
ICP47 and US 11 to prevent epitope presentation may be negated during an inflammatory 
response. To evaluate this issue, VA13 fibroblasts and MOLT-3 lymphoblasts were cultured 
in media containing IFNy. Co-expressing ICP47 and US11 in human fibroblasts can lead to 
a complete loss of cell surface class I MHC (Berger gf a/., 2000). In our study of VA13 
human fibroblasts, ICP47 and US 11 decreased cell surface class I MHC by 73% and 64% 
respectively. Subsequent incubation with a relevant level of IFNy (400 lU/ml) resulted in a 
greater than 3 fold increase of class I MHC levels in transduced and non-transduced cells and 
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minimized the ICP47 and US 11 effects observed (Fig. 7)(Saito ef of., 1983). These data 
suggest a potential limitation in an m vfvo setting. A systemic cellular immune response 
against transduced cells may lead to the release of IFNy overriding the class I MHC 
suppression induced by ICP47 and US11 thereby revealing the transgene being protected. A 
less prominent upregulation effect was observed when MOLT-3 human lymphoblasts were 
studied (Fig. 7). These findings suggest that careful testing and evaluation will be required to 
apply this immune evasion technique and its application will be transgene and cell type 
specific. Given the wide variation in epitope immunogenicity, the effectiveness may differ 
greatly for specific transgenes. Although it may be possible to overcome IFNy increased 
class I MHC levels by simply increasing the number of inhibitory molecules present, 
constitutive expression of ICP47 or US11 at a significantly higher level may be difficult to 
achieve. A potentially attractive approach may be to use IFNy inducible promoters to 
increase ICP47 and US11 expression coincident with increase in transcription of the class I 
MHC genes. IFNy inducible promoters have been characterized from several class I and II 
MHC genes and have been shown to function in transgene models (Eades ef a/., 1990; Sims 
eW.,1993). 
In conclusion, ICP47 and US11 decrease class I MHC in a wide variety of cell types. 
This ability makes them attractive potential candidates for inducing localized immune 
suppression to delivered transgenes. Two obstacles to the application of ICP47 and US11 for 
use in suppression of host CTL response to transgene were examined. First, cell line 
variability in the function of ICP47 and US11 demonstrates the need to specifically tailor the 
vector to the target cell type being treated. Such narrowly optimized vectors would limit 
application where multiple tissues are involved, such as with organ transplants or with m Wvo 
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transduction. Second, the up regulation of class I MHC by inflammatory cytokines needs to 
be further addressed to achieve the goal of long term suppression of CTL mediated lysis. 
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Figure 1. Schematic representation of the LISN and LUSN retroviral vectors and 
detection of the transgene expression in the A375 melanoma cells. (A) Both ICP47 and 
US 11 were cloned into LXSN at the Eco RI restriction site. Abbreviations: LTR Long 
Terminal Repeat, EPS Extended Packaging Signal, SV40 SV40 promoter, Neo* 
Neomycin Phosphotransferase, ICP47 308 nucleotide gene sequence cloned into the 
EcoR I site (see methods) encoding the HSV ICP47 gene, US11 689 nucleotide gene 
sequence cloned into the EcoR I site (see methods) encoding the hCMV US11 gene. (B) 
Northern analysis of RNA expression in the A375 cell line. Three separate probes detect 
the Neo*, the ICP47, and the US 11 RNA transcripts at their expected sizes. 
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Figure 2. A375 human melanoma cells transduced with US 11 or ICP47 retroviral 
vectors exhibit reduced cell surface expression of MHC I. (A) NV (No Vector), LXSN, 
LISN, LUSN transduced A375 cells were labeled with the H58A MAb that recognizes a 
conserved MHC I epitope. A FITC labeled anti-mouse secondary Ab was used and the 
samples were analyzed by flow cytometry. The control is an untransduced A375 sample 
labeled with Isotype matched (IgG2a) primary MAb and the same FITC secondary Ab. 
(B) Where single peaks were observed, the mean fluorescence was graphed. The percent 
decrease in expression (j.%) was determined by subtracting the negative control from the 
experimental values and calculating the decrease compared to the LXSN transduced. 
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Figure 3. Multiple human cell lines transduced with ICP47 or US 11 retroviral vectors 
exhibit reduced cell surface expression of MHC I. Transduced mixed populations of cells 
were labeled with anti-MHC I Ab and a FITC labeled secondary. A single peak from 
flow cytometry analysis is reported as the mean fluorescence intensity. Control 
represents isotype matched Ab plus the FITC labeled secondary Ab. The percent 
decrease in expression (j.%) was determined by subtracting the negative control from the 
experimental values and calculating the decrease in expression compared to LXSN 
transduced cells. (A) SW620 colorectal adenocarcinoma. (B) A549 lung carcinomma. 
(C) 293 transformed human kidney fibroblasts. (D) IGROV ovarian adenocarcinomma. 
(E) OVCAR ovarian adenocarcinomma. (F) DU 145 metastatic prostate carcinoma. 
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Figure 4. ICP47 and US11 function in dog and rat cells. (A) Rat brain gliosarcoma 9L, 
and (B) Canine osteosarcoma D17 cells were transduced with LXSN, LISN, and LUSN 
vectors. Transduced and non-transduced cells were assayed for cell surface class I MHC 
as previously described. 
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Figure 5. Expression of both ICP47 and US 11 in the same cell line leads to further 
decrease in cell surface MHC I. (A) Schematic representation of the USl 1 in MSCVp 
vector. MSCVp is an alternate murine Molony leukemia virus based retrovirus 
containing a murine stem cell virus promoter and a puromycin selection marker (Puro*) 
driven by the PGK (PhosphoGlycerate Kinase) promoter. (B) A375 and (C) VA13 cells 
were transduced with both vectors and assayed for class I MHC expression. 
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Figure 6. ICP47 and US11 protect A375 cells from lysis by anti-A375 primed effector 
cells. Peripheral blood mononuclear cells (PBMC) were isolated from two random 
donors and co-cultured with irradiated A375 cells for 14 days to generate an anti-A375 
effector cell populations. Specific lysis was determined by the release LDH from dying 
cells (see methods) (A) PBMC (15% CDS* data not shown) isolated from random donor 
number 1. (B) CDS* enriched effector cell population (82% CDS* data not shown) 
generated using a CD4^ depletion column on PMBC from donor 2. 
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Figure 7. Incubation of cells in media containing IFNy restores cell surface MHC I 
expression in the VA13 and Molt-3 cell lines. IFNy is a common cytokine known to 
upregulate MCHI expression. (A) Molt-3 acute lymphoblastic leukemia and (B) VA13 
transformed human fibroblast cells were transduced with the LXSN, LISN, and LUSN 
vectors. Cells were incubated with 400 I U/ml IFNy for 72 hr and cell surface class I 
MHC was determined as before. 
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CHAPTER 3. TALL-104 CYTOTOXICITY CORRELATES WITH THE LEVEL OF 
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ABSTRACT 
The acute T lymphoblastic leukemia cell line, TALL-104, is in clinical testing for 
its ability to preferentially kill tumor cells. The ability of TALL-104 cells to lyse tumor 
targets of multiple class I MHC haplotypes as well as targets from other species led to their 
designation as class I MHC nonrestricted. Our current data also demonstrated that TALL-
104 cytotoxic activity correlates with expression of class I MHC on human cells in a 
nonrestricted manner. Two class I MHC positive cell lines A375 melanoma, VA13 
fibroblasts, and two class I MHC negative cell lines, K562 leukemia, and HCT15 colon 
cancer, were transduced with retroviral vectors encoding two viral genes that are known to 
decrease class I MHC cell surface levels. The herpes simplex virus type IICP47 and the 
human Cytomegalovirus US11 gene product use differing mechanisms to decrease cell 
surface class I MHC. Interestingly, both genes reduce TALL-104 lysis of targets as compared 
to cells transduced with control vectors. ICP47 transduced class I MHC positive cells 
decreased cell surface expression of class I MHC by 66-69% and the corresponding lysis by 
TALL-104 cells dropped 32-34%. USl 1 transduced class I MHC positive cells decreased cell 
surface expression of class I MHC by 73-97% and the corresponding lysis by TALL-104 
cells dropped 43-59%. Class I MHC negative cells transduced with either gene showed no 
change in their susceptibility to TALL-104 lysis. The ability to spare normal cells while 
killing a wide array of tumor cells indicates a tumor specific TALL-104 activity mediated by 
molecules present on virtually all cell types and conserved across species. Highly conserved 
regions of class I MHC and class I MHC associated molecules fulfill this criterion and may 
explain the data presented here. In contrast to traditional class I MHC associated killing, 
TALL-104 cells also exhibit NK surface markers and kill class I MHC negative cells 
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efficiently. The presence of NK markers and the ability to kill NK sensitive cells implies that 
TALL-104 cells can also kill class I MHC negative tumors using a traditional NK 
mechanism. Understanding how TALL-104 cells recognize targets has the potential to 
improve the clinical application of these cells and may indicate a novel anti-tumor response. 
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INTRODUCTION 
CD3\ CD8*, TCR lymphocytes typically are cytotoxic against target cells in a 
manner restricted by peptide presentation on class I MHC molecules. Although TALL-104 
cells display these markers, they lyse a broad range of tumor cells in a class I MHC 
nonrestricted manner (1, 2). Their ability to lyse tumor cells crosses species and has been 
exploited with promising results in both dog and human clinical trials (3-5). In addition to 
expressing markers consistent with CTL, TALL-104 cells are CD 56* similar to both NK and 
LAK cells and secrete several cytokines including IFNy and TNFa when stimulated through 
contact with tumor cells (1, 6). In accordance with their abundance of cell surface markers, 
TALL-104 cells kill targets using two distinct mechanisms; release of cytolytic factors and 
induction of apoptosis (2). The broad range of tumors lysed by TALL-104 cells includes 
typical NK targets lacking cell surface class I MHC and normally NK resistant class I MHC 
positive cells. Thus, Tall-104 cells have many characteristics of both NK. and CTL cells. 
Understanding how these cells recognize targets may aid in improving their clinical 
application and provide new insight into their unique abilities to target a broad range of 
tumors. 
Class I MHC molecules are known to trigger peptide restricted CTL mediated lysis 
by their presence and NK mediated lysis by their absence. To explore the potential 
contribution of class I MHC molecules in TALL-104 recognition and lysis of targets, two 
class I MHC inhibitors were employed. Infected cell protein (ICP)47 is an HSV type I 
protein encoded by a 267 nucleotide immediate early gene (7). ICP47 binds to the 
cytoplasmic side of the Transporter associated with Antigen Processing (TAP) and blocks the 
transport of 8-9 amino acid peptides into the Endoplasmic Reticulum (ER) (8, 9). Without 
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these peptides, class I MHC molecules are degraded and therefore not displayed at the cell 
surface (10). A second Herpes virus protein that prevents cell surface class I MHC 
expression is encoded by the 645 nucleotide human Cytomegalovirus (HCMV) gene US11 
(11). US11 binds to mature class I MHC molecules and dislocates them back to the 
cytoplasm where they are rapidly degraded (12, 13). Although they work by different 
mechanisms, both genes have proven effective at decreasing cell surface class I MHC in a 
variety of cell types (14). In this study, ICP47 and US 11 inhibitors of class I MHC 
expression are used in multiple cell lines and the effects on TALL-104 cytotoxicity are 
reported. 
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MATERIALS AND METHODS 
Vector construction. Polymerase chain reaction (PGR) amplification of the ICP47 
gene from purified HSV DNA (Sigma-Aldrich Corp., St. Louis, MO) and the US 11 gene 
from HCMV DNA (Sigma-Aldrich Corp.) was performed and the products were cloned into 
the T/A cloning vector PCR 3.1 (Invitrogen Inc., Carlsbad, CA). ICP47 and US11 were 
excised from PCR3.1 using the restriction endonuclease Hind III and each sub-cloned into 
the murine retrovirus derived LXSN vector at the Hind III site in the multicloning region (15) 
(Figure I). 
Cell lines. The LISN, LUSN, and control LXSN vectors were each transfected into 
the GP+E86 cell line (16). Supematants were collected, filtered, (0.2 pm) and used to 
transduce PA317 amphotropic vector producer cells (VPC) (17). PA317 cells were selected 
for in the neomycin homologue G418 (1 mg/ml) for 2 weeks and supematents were used to 
transduce the following cell lines: A375 human malignant melanoma (18); VA13 SV40 
transformed human fetal fibroblast (19); K562 human lymphoblast (20); HCT15 colorectal 
adenocarcenoma (21). TALL-104 cell cultures were maintained in the recommended 
medium (American Type Culture Collection, Rockville, MD). 
Class I MHC Expression assay. Transduced, mixed populations of cells were 
briefly trypsinized and labeled with anti-class I MHC monoclonal Ab H58A (VMRD Inc., 
Pullman, WA) at 1.5 pg/ml/0.5x 10* cells in serum free media at 37°C for 1 hr (22). The anti-
mouse IgG2a isotype control UPC 10 Ab was used to control for nonspecific binding 
(Sigma-Aldrich Corp.). Cells were washed 5 min in Hank's buffer and a 1:64 dilution of 
goat anti-mouse FITC labeled secondary Ab (Sigma-Aldrich Corp.) in serum free media was 
added for 30 min at 37*C. Cells were again washed 5 min in Hank's buffer and resuspended 
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in Phenol red free/serum free media (OptiMEM*, Invitrogen Corp., Inc.Grand Island, NY) 
for fluorescent analysis. Where a single peak was observed, the mean fluorescence intensity 
is reported. The same protocol as above was used to detect cell surface expression of p2 
microglobulin ((32m) with the primary Ab being BM-63 which recognizes a conserved region 
of P2m (Sigma-Aldrich Corp.). The anti-mouse IgGl isotype control MOPC 21 Ab was used 
to control for nonspecific binding (Sigma-Aldrich Corp.). Data shown is a representative 
result from a minimum of 3 experiments. For IFNy stimulation of class I MHC, cells were 
cultured 72 hr in media containing 400U/ml IFNy with fresh media replacement after the first 
48 hr. 
Cytotoxicity Assay. A non-radioactive colorimetric assay was used to determine 
specific cytotoxicity of TALL-104 effector cells against vector transduced and control target 
cells. The Cytotox* 96 (Promega Inc., Madison, WI) assay measures lactate dehydrogenase 
(LDH) release by a reaction with a tetrazolium salt (INT) to produce a red fbrmazan product 
(23). In brief, target cells are plated in a 96 well plate and effector cells are added at the 
appropriate ratio. After 4 hr, supernatant is collected and assayed for LDH content. Controls 
include maximum LDH release (detergent lysed), media background, and spontaneous LDH 
release from both targets and effector cells. Each data point is an average of 4 wells and data 
presented is a representative result from a minimum of two experiments. 
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RESULTS 
TALL-104 lysis of class I MHC positive cells correlates with the amount of class 
I MHC on the cell surface. Using class I MHC inhibitors introduced by retroviral 
transduction allows for the generation of cell populations derived from a parental line that 
maintain a consistent, decreased cell surface level of class I MHC while introducing a 
minimal number of variables. Using two class I MHC inhibitors that function through 
distinct mechanisms minimizes the potential that either inhibitor has an undefined effect on 
TALL-104 lysis of target cells. A375 melanoma cells transduced with the LISN or LUSN 
vectors express a decreased level of class I MHC on the cell surface (Figure 2A). Class I 
MHC presentation is decreased by 66% using LISN and 97% using LUSN as compared to 
the LXSN transduced control population. In subsequent cell killing assays using TALL-104 
cells as effectors and the transduced populations as targets, cells with less Class I MHC 
expression are killed less efficiently by TALL-104 cells. At an effector to target ratio of 
10:1, TALL-104 specific cytotoxicity decreased by 32% and 43% against LISN and LUSN 
transduced populations respectively, as compared to the LXSN transduced control (Figure 
2B). As these were unexpected results using a class I MHC nonrestricted effector cell, a 
second class I MHC positive cell line was transduced and analyzed. 
In transduced VA13 fibroblast cells, class I MHC presentation is decreased by 69% 
using LISN and 73% using LUSN over levels measured in the LXSN transduced cells 
(Figure 3 A). Measuring specific cytotoxicity of TALL-104 cells against VA13 targets at an 
effector target ratio of 5:1, LISN and LUSN decrease cytotoxicity by 34% and 59% 
respectively. Thus, in both the A375 and VA13 cell lines, when cell surface class I MHC is 
decreased by two distinct mechanisms, specific lysis by TALL-104 cells is also decreased. 
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TALL-104 lysis of K562 cells. K562 lymphoblast cells are often used as a class I 
MHC negative cell line to identify and quantitate NK cell killing activity. K562 cells are one 
of several class I MHC negative cell lines that are efficiently killed by TALL-104 cells (2). 
The ability of TALL-104 cells to kill class I MHC negative and positive cells along with their 
being TCR a|3* led to their designation as class I MHC nonrestricted. TALL-104 killing of 
class I MHC negative cells is not completely unexpected as they also express cell 
determinant markers consistent with both NK and LAK cells (1). If however TALL-104 
cells also use class I MHC levels to select targets, neither ICP47 nor US11 should have an 
effect on TALL-104 lysis of K562 cells. A complicating factor when using K562 cells as 
targets is their expression of class I MHC epitopes when grown in media containing IFNy. 
The amount of class I MHC increase has been shown to inhibit their susceptibility to NK 
mediated killing (24-26). Upon contact with target cells, TALL-104 cells upregulate 
transcription of the IFNy genes with a maximum level reached within 2 hr (6). Appearance 
of cell surface class I MHC on K562 cells could have complicated the interpretation of 
cytotoxicity results. To investigate this possibility, transduced and NV control K562 cells 
were grown in media with and without IFNy (400IU/ml) and class I MHC levels were 
assayed (Figure 4A). Growth in media containing IFNy caused all the K562 cell lines to 
express cell surface class I MHC. LISN and LUSN transduced lines displayed 20% and 71% 
less class I MHC on the cell surface as measured by flow cytometry compared to the LXSN 
transduced control. In subsequent cytotoxicity assays, there was minimal difference between 
the specific cytotoxicity of TALL-104 cells against K562 cell lines grown with or without 
IFNy. The potential involvement of two distinct killing mechanisms demonstrates a 
significant drawback to using K562 cells as a class I MHC negative control when effector 
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cells release IFNy. An improved control for this experiment would require a cell line unable 
to express class I MHC regardless of cytokine involvement. 
Lack of class I MHC expression in HCT15 cell lines and corresponding TALL-
104 lysis patterns. The HCT15 cell line was transduced with the LXSN, LISN, and LUSN 
vectors. With the NV parental control cells, these four cell lines were grown in media with 
and without IFNy. All four cell lines were then analyzed for cell surface expression of class I 
MHC and the associated (12m proteins (Figure 5A). Flow cytometry analysis detected no 
expression of class I MHC or P2m with or without IFNy addition to the media. The complete 
lack of class I MHC and p2m makes HCT15 cells a better negative control than K562 to 
determine the effect of class I MHC on TALL-104 killing. TALL-104 cytotoxicity against 
the HCT15 cell lines with or without IFNy shows no differences (Figure 5B). Thus, neither 
ICP47 nor US11 have an effect on TALL-104 killing of HCT15 cells lacking both class I 
MHC and (S2m. 
Direct comparison of TALL-104 killing in class I MHC positive and negative cell 
lines. To determine whether class I MHC positive or negative target cells are more 
efficiently killed by TALL-104 effector cells, K562, HCT15, VA13, and A375 cells were 
tested as targets at a target:effector ratio of 10:1 (Figure 6). The two class I MHC negative 
cell lines presented the best targets for TALL-104 killing with HCT15 and K562 cells being 
killed 93% and 58% respectively. The class I MHC positive cells VA13 and A375 were 
killed 45% and 28% respectively. These data suggest that clinical use of TALL-104 cells 
may be more effective when used to treat class I MHC negative tumors. 
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DISCUSSION 
TALL-104 cells have shown promise when used to treat cancer in both dog and 
human clinical trials (3, 5). Their ability to lyse tumor cells while bypassing normal tissue 
may be a side effect of their transformation or may represent a novel anti-tumor immune 
mechanism. Whatever the identified mechanism by which TALL-104 cells recognize and 
kill tumor targets, the data may aid the design of further clinical trials of this cell therapy. 
Their ability to lyse class I MHC negative cells even though they are CDS* and TCRa(3* led 
to their designation as class I MHC nonrestricted (27). Class I MHC is known to play a key 
role in both NK and CTL mediated targeting and lysis. To investigate whether class I MHC 
functions in the TALL-104 recognition of tumors, two distinct class I MHC inhibitors were 
employed. By decreasing class I MHC expression in A375 melanoma and VA13 fibroblast 
cells using retroviral vectors encoding inhibitory proteins, the effect on TALL-104 lysis was 
evaluated while introducing a limited number of variables. In both the A375 and VA13 cell 
lines, when the level of cell surface class I MHC was decreased, the specific lysis by TALL-
104 cells also decreased (Figures 2 and 3). Using two distinct class I MHC inhibitors 
minimized the possibility that either molecule might affect TALL-104 cytotoxicity in a 
manner independent of their described specific class I MHC inhibition mechanisms. These 
data establish evidence that class I MHC or an associated molecule is involved in TALL-104 
targeting of these cell types. 
TALL-104 cells also express the NK marker CD56 suggesting that they may be 
killing class I MHC negative cells using a traditional NK killing method. In class I MHC 
negative K562 and HCT15 cells, neither ICP47 nor US 11 had any significant effect on 
TALL-104 lysis. However, an exception to this occurs in K562 cells grown in media 
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containing IFNy that induces cell surface expression of class I MHC. Interestingly when 
encountering target cells, TALL-104 cells secrete IFNy with maximum levels of RNA 
detected within 2 hr (6). Although maximum upregulation of class I MHC by IFNy has been 
reported to take up to 48 hr, class I MHC is known to accumulate at the cell surface at sites 
of cell-cell contact (28, 29). Thus, during a 4 hr cytotoxicity assay, the stimulation and 
secretion of IFNy followed by upregulation of class I MHC may play a role in TALL-104 
mediated lysis of K562 cells. In general, the IFNy upregulation of class I MHC led to only 
slightly increased TALL-104 lysis of K562 cells. However, since two possible mechanisms 
may be occurring simultaneously further experiments were conducted with a cell line that 
does not upregulate class I MHC in response to IFNy (Figure 4). 
One such cell line is the HCT15 colon cancer cell line. HCT15 cells do not express 
either class I MHC or (32m when grown in the presence or absence of IFNy (Figure 5A). 
TALL-104 lysis of HCT15 cells is unaffected by growing the cells in IFNy or by transduction 
with the LISN or LUSN vectors (Figure 5B). The data in HCT15 cells demonstrates clearly 
that neither ICP47 nor US11 alter TALL-104 mediated lysis. These combined results with 
A375, VA13, and HCT15 cells, indicate that class I MHC apparently plays an important role 
in TALL-104 recognition of class I MHC positive tumor cells, but no role in the lysis of class 
I MHC negative cells. The presence of tumor associated antigens within cancer cells may 
increase the overall epitope presentation by class I MHC. This increased epitope 
presentation perhaps could contribute to the selective killing of cancer cells by TALL-104 
lysis. Together these two apparently separate methods of killing by TALL-104 cells may 
account for the sensitivity of a wide array of tumor cell targets. However, the m vzfro data 
when directly compared, suggests that the class I MHC negative cell lines K562 and HCT15 
76 
are better targets for TALL-104 lysis (Figure 6). These results suggest the importance of 
further study of TALL-104 cells to optimize their clinical utility. The two current trials of 
TALL-104 are for bone marrow purging and direct transplant and may have an improved 
opportunity for success against class I MHC negative tumors. 
The ability of TALL-104 cells to lyse such a broad range of targets implies the mode 
of recognition is present on many if not most cell types. If TALL-104 cells are using their T-
Cell Receptor (TCR) to interact with class I MHC, it suggests the possibility that MHC 
dominant binding is occurring at a conserved or nonpolymorphic site. This would account 
for TALL-104 recognition of tumor targets regardless of class I MHC haplotype. The class 
la (classical) MHC molecules (HLA-A, -B, -C) are expressed on nearly all cell types, have 
highly conserved regions in addition to their polymorphic regions, and thus are potential 
candidates as TALL-104 ligands. Of the class lb (nonclassical) MHC molecules (HLA-E, -F, 
-G, -H, MICA, MICB, and CDl-a, -b, -c, -d) only HLA-E is constitutively expressed on most 
cell types (reviewed in (30)). In addition to their expression in very few cell types, HLA-G 
has been shown to be USl 1 resistant (31, 32) and CDID functions independent of the TAP 
transporter indicating neither could be responsible for the class I MHC response 
demonstrated in the current study (33). In contrast, HLA-E is relatively nonpolymorphic, is 
expressed on virtually all cell types, and has been shown to play a key role in NK 
recognition and lysis (34-36). Ongoing experiments are now focusing on identifying the 
specific class I MHC molecule involved in the TALL-104 interaction. 
Recent publications support the concept that MHC dominant binding may not be an 
aberrant byproduct of tumorigenesis, but rather represent a mechanism of normal anti-tumor 
immune surveillance. The K14 cell line is a CD8^ TCRop* clone expressing the NK marker 
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NKG2C that has been shown to recognize an HLA-E molecule complexed with several 
different peptides derived from both class I MHC leader and viral sequences (37). This 
MHC dominant binding resembles in principle the nonspecific class I MHC interaction seen 
in TALL-104 cells. Additionally, populations of clonally expanded human CDS* TCRa{3* 
cells have been isolated from peripheral blood of healthy donors that show a specific 
response to HLA-E/p2m that can be blocked by various monoclonal antibodies (38). This 
population of cells, called NK-CTL, also display NK inhibitors and appears to have function 
similar to TALL-104 cells with the distinction that they require target cell expression of f)2m 
for lysis to occur (39). TALL-104 lysis of the P2m negative cell line HCT15 may be 
explained by an additional NK mediated lysis mechanism Like TALL-104 cells, the K14 
clone and NK-CTL cells are CD8*, TCRa|3*, display NK markers, and lyse a broad range of 
tumor targets regardless of class I MHC haplotype (40). Unlike TALL-104 cells which have 
a identified mutation associated with a tumor genotype (1), both the K14 clone and the NK-
CTL populations were isolated from healthy donors implying their normal function may be 
tumor surveillance and eradication. Murine cells displaying similar cell surface markers and 
having cytolytic activity against a broad range of tumor targets have also been reported (41). 
As more examples of this nonspecific anti-tumor activity are identified, their roles in tumor 
immunity will be better understood. 
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Figure 1. Schematic representation of the LISN and LUSN vectors used. The LISN and 
LUSN vectors were constructed from the LXSN murine retroviral vector. The 5' LTR 
(long terminal repeat) contains a promoter that drives transcription of the gene inserted in 
the multi cloning site. PGR primers shown designate orientation 5'-3% coding sequence 
(zWzcizeef), and the restriction endonuclease Hindlll (bold). 
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5' GCAAGCTTGAAGCGCGTATGTCGTGGGCCCTGGA4ATGGCG 3' 
Extended Packaging Signal 
LTR HSV ICP47 
Neomycin Phosphotransferase 
3' GGGGCAT7*GGCCW7TGGGCAACT TTCGAACG 5' 
LISN (6182 bp) 
5' GÇAACGTTGAAGCGCGT^TGA4CC7TG7%ATGCTMTTC7X 3' 
Neomycin Phosphotransferase 
Dr 
Extended Packaging S* 
HCMV LTR 
3' ACC7*CW/VWGCCrGGrCACCWCr TTCGAACG 5' 
LUSN (6563 bp) 
Figure 2. Class I MHC expression and TALL-104 lysis of A375 cell lines. A375 cell 
lines including NV, LISN transduced, and LUSN transduced. A) Flow cytometry 
analysis of populations to determine inhibition of class I MHC cell surface expression. 
Single peaks from histograms are reported as mean fluorescence. B) Percent speciGc 
cytotoxicity of TALL-104 cells against the A375 cell lines at effector to target ratios of 
10:1 to 1.25:1 in a 5 hr LDH release assay. 
% Specific Cytotoxicity ^ 
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Figure 3. Class I MHC expression and TALL-104 lysis of VA13 cell lines. VA 13 cell 
lines including NV, LISN transduced and LUSN transduced. A) Flow cytometry 
analysis of class I MHC inhibition. B) Percent specific cytotoxicity of TALL-104 cells 
against the VA13 cell lines at effector to target ratios of 5:1 to 1.25:1 in a 5 hr LDH 
release assay. 
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Figure 4. IFNy effect on class I MHC presentation and TALL-104 lysis of K562 cell 
lines. K562 cell lines including NV, LISN transduced, and LUSN transduced. A) Flow 
cytometry analysis of class I MHC expression both with and without IFNy stimulation. 
B) Percent specific cytotoxicity of TALL-104 cells against the K562 cell lines with and 
without IFNy stimulation at effector to target ratios of 5:1 to 1.25:1 in a 5 hour LDH 
release assay. 
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Figure S. TALL-104 lysis of the class I MHC negative cell line HCT15. HCT15 cell 
lines including NV, LISN transduced, and LUSN transduced. A) HCT15 cells lack cell 
surface expression of both class I MHC and P2m regardless of the presence of IFNy in 
the growth medium. B) Flow cytometry analysis of TALL-104 cytotoxicity against the 
class I MHC negative HCT15 cell lines in a 4 hr LDH release assay. 
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lines. Flow cytometry analysis of TALL-104 specific cytotoxicity against the four cell 
lines used in this study at an effector:target ratio of 15:1 in a 3 br LDH release assay. 
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CHAPTER 4. APPLICATION OF CLASS I MHC IMMUNE SUPPRESSION FOR 
USE IN ALLOGENEIC TRANSPLANT AND TUMOR MODEL 
CELL EVASION OF HOST RESPONSE. 
ABSTRACT 
Class I MHC inhibition by ICP47 and US11 has been achieved in a variety human, 
canine, and rodent cell lines. Although this represents down regulation of only one aspect of 
host immune response, it may be possible to use this inhibition to achieve specific short-term 
immune suppression goals. In this application, the immune suppression delivered serves as 
the therapeutic treatment Allogeneic transplant of anti-tumor cells is one treatment that 
could benefit from short-term suppression of host CTL response. There are at least two cell 
lines that are currently under investigation for their potential to treat various tumors. The 
CD8\ TCRaP*, CD56\ T Acute Lymphocytic Leukemia (TALL)-104 cell line has 
demonstrated an ability to kill tumor cells while sparing normal tissue. This cell line has 
been used in clinical trials to treat cancer in both dogs and humans and has shown promising 
results. In humans, vigorous CTL responses have been documented to the TALL-104 cells 
used in the treatment If class I MHC expression were reduced or eliminated 6om TALL-
104 cells, their duration in patient may increase and improve the effectiveness of the 
treatment. NK-92, a natural killer (NK) cell line with similar function to TALL-104 has also 
been characterized and is under investigation for use in treating cancer. Both of these cell 
lines were transduced with retroviral vectors expressing ICP47 and US11 and the resulting 
class I decrease is reported herein. A third application of short-term class I MHC aims to 
prolong the survival of reintroduced tumor cells generated from outbred mice for use as a 
tumor model. After isolating and establishing primary tumor cell lines, it is often difficult to 
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achieve tumor growth when the cells are reintroduced back into mice. With outbred mice, 
host immune responses are likely candidates for the inability to sustain tumor growth. By 
suppressing class I MHC expression, tumor cells may be able to establish Wvo for a long 
enough period of time to provide a useful model system. Preliminary results for these three 
applications of class I MHC suppression are presented and their significance discussed. 
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INTRODUCTION 
One form of cancer treatment now in clinical trials involves transplanting allogeneic 
lymphocytes that preferentially kill tumor cells into patients with the hope that these 
lymphocytes will locate and kill tumor cells m vfvo. In an alternate form of this approach, 
cancer cells can be purged ûom a patient's bone marrow ex vfvo while the patient undergoes 
aggressive cancer treatment After treatment, the purged bone marrow with its resident 
population of pluripotent stem cells is reintroduced to repopulate the patient's blood system. 
TALL-104 and NK-92 demonstrate an ability to kill tumor cells preferentially and are 
currently undergoing clinical trials to treat a number of different types of cancers. Because 
these are both cancer cell lines, they are irradiated to a point where they maintain their 
cytotoxic functions while losing the ability to divide before they are administered to patients. 
The TALL-104 cell line has demonstrated a remarkable ability to kill tumor cells 
from a number of species while sparing normal tissue [1-3]. To exploit this ability, three 
clinical trials to treat cancer have been performed [4-6]. The TALL-104 cells are irradiated 
to avoid transferring leukemia to the patients and injected in escalating doses throughout the 
treatment Two trials treating both spontaneous and introduced tumors in dogs provided 
promising results. A third Phase I clinical trial to treat refractory metastatic breast cancer in 
humans demonstrated mixed results. Over the course of the treatment, 7 of 15 patients 
developed specific CTL responses to TALL-104 cells which likely limited the time TALL-
104 cells were available to attack tumors [6]. In a previous clinical trial, anti HIV CD8* cells 
transduced with a retroviral vector encoding a marker gene were administered to HIV 
immunocompromized patients [7]. Initial injections of marked lymphocyte were detectable 
by polymerase chain reaction (PCR) assay at decreasing levels far the first seven days. With 
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subsequent injections into these now primed patients, labeled cells were often undetectable 
even one day post injection. Thus, with haplotype mismatched TALL-104 cells presenting 
unknown numbers of non-self antigens, the prospect of effective cancer killing cells 
remaining in the patients any significant time seems minimal. By decreasing the presentation 
of class IMCH antigens on TALL-104 cells, we hope to prolong their persistence in patients 
and improve their effectiveness at treating cancers. 
NK-92 is a NK cell line that has been shown to preferentially kill tumor cells similar 
to TALL-104 cells [8-10]. Clinical trials using NK-92 are now under way [11, 12]. How 
NK-92 cells function to recognize and kill tumor cells is not yet understood, but much like 
TALL-104 cells it involves a class I MHC non restricted process [13]. NK-92 cells appear to 
be particularly effective when used for er-vivo bone marrow purging [14, 15]. During this 
bone marrow purging process, NK-92 cells are exposed to host CTL and thus would likely 
benefit by having less cell surface class I MHC presenting targets. By decreasing the 
presentation of class I MCH antigens on NK-92 cells, we hope to improve their utility for 
both bone marrow purging and allogeneic transplant 
A third application of class I MHC suppression addressed herein involves a need to 
prolong the survival of chemically induced tumors when re-introduced back into mice in 
order to establish a cell line suitable for use as an m vivo tumor model. Cell lines established 
from tumors may have difficulty growing in their host organism for a variety of reasons. 
Inability to establish a necessary blood supply, introduction to a new tissue site, and a variety 
of immunological barriers are some of the challenges these tumor cells need to overcome. 
By decreasing class I MHC presentation on tumor cells, they may be able to avoid CTL 
recognition and lysis long enough to establish a tumor. The specific tumor model chosen 
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involves an in-house generated squamous cell carcinoma of the dermis, SQ172 [16]. This 
tumor was generated using a chemical carcinogenesis regimen on a a (1,3) 
galactosyltransferase (a-gal) knockout outbred mouse. SQ172 was determined to be H-2^ 
haplotype however re-introduction into H-2^ matched a-gal knockout mice at varying doses 
resulted in regression of tumors beginning at 7-10 days post injection. Seven days is the 
average time for peak CTL response indicating the possibility that CTL recognition of minor 
antigens was responsible for the failure to establish tumors. To investigate this further, the 
SQ172 cell line was transduced with the LUSN vector to determine the effect on class I 
MHC expression and vhw growth properties. 
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MATERIALS AND METHODS 
Vectors and cell lines. The LEL vector consists of an LXSN vector with the SV40 
promoter and Neo* gene deleted and replaced with the eGFP gene. The LESN vector 
consists of an LXSN vector with the eGFP gene cloned into the multicloning site. PA317 
retrovirus packaging cell lines were developed for the LEL, LESN, LXSN, LISN, and LUSN 
vectors to obtain the supematants necessary for transduction. Eight serial transductions of 
TALL-104 and NK-92 cells were done using freshly prepared viral supematants. The 
following cell lines were used as targets in cytotoxicity assays: A375 human malignant 
melanoma [17]; VA13 SV40 transformed human fetal fibroblast [18]; K562 human 
lymphoblast [19]; HCT15 colorectal adenocarcenoma [20]; SQ172 squamous cell carcinoma 
of the dermis. TALL-104 and NK-92 cell cultures were maintained in the recommended 
medium (American Type Culture Collection, Rockville, MD). 
Class I MHC Expression assay. Transduced, mixed populations of cells were 
briefly trypsinized and labeled with anti-class I MHC monoclonal Ab H58A (VMRD Inc., 
Pullman, WA) at 1.5 ng/ml/0.5xl0* cells in serum free media at 37" for 1 hr [21]. The anti-
mouse IgG2a isotype control UPC 10 Ab was used to control for nonspecific binding 
(Sigma-Aldrich Corp.). Cells were washed 5 min in Hank's buffer and a 1:64 dilution of 
goat anti-mouse FTTC labeled secondary Ab (Sigma-Aldrich Corp.) or for 2 color analysis a 
1:20 dilution of anti-mouse R-Phycoerithrin labeled secondary Ab (Sigma-Aldrich Corp.) 
were added for 30 min at 37°. Cells were again washed 5 min in Hank's buffer and 
resuspended in Phenol red free/serum free media (OptiMEM*, Invitrogen Corp., Inc.Grand 
Island, NY) 6r fluorescent analysis. Where a single peak was observed, the mean 
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fluorescence intensity is reported. Data shown is a representative result from a minimum of 
2 experiments. 
Cytotoxicity Assay. A non-radioactive colorimetric assay was used to determine 
specific cytotoxicity of NK-92 efkctor cells against vector transduced and control target 
cells. The Cytotox* 96 (Promega Inc., Madison, WI) assay measures lactate dehydrogenase 
(LDH) release by a reaction with a tetrazolium salt (INT) to produce a red fbrmazan product 
[22]. In brieG target cells are plated in a 96 well plate and effector cells are added at the ratio 
of 15:1. After 5 hrs, supernatant is collected and assayed for LDH content Controls include 
maximum LDH release (detergent lysed), media background, and spontaneous LDH release 
from both targets and effector cells. Each data point is an average of 4 wells and data 
presented is a representative result from a minimum of two experiments. 
Mouse Injections. SQ172 cells were seeded, grown 24 hrs, counted and resuspended 
to 1x10* or 5x10^/1 OOul in HBSS. Female, 8-14 week old a-gal knockout mice were injected 
subcutaneously in the belly and tumor measurements were taken 2-3 times weekly. Tumors 
were measured length x width x height and animals with ulcerated tumors or tumors larger 
than 1 cm^ were euthanized. 
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RESULTS 
Retroviral eGFP transduction into TALL-104 and NK-92 cells. Efficient 
MoMLV transduction into lymphocytes can be difficult to achieve [23-25]. To determine if 
TALL-104 or NK-92 cells could be transduced, two vectors encoding humanized, red-shifted 
green fluorescent protein (eGFP) were used [26]. LEL encodes eGFP and has had the SV40 
promoter and Neo* gene deleted. LESN is a LXSN vector with the eGFP gene cloned into 
the multicloning site. After eight consecutive transductions, fluorescent cells were observed 
in TALL-104 and NK-92 populations transduced with either vector. 4-5% of NK-92 cells 
were eGFP positive in either the LEL or the LESN populations indicating that for each of the 
eight transductions approximately 0.5% of the NK-92 cells were transduced (data not 
shown). Viral supernatant was prepared fresh for each transduction and viral titers were not 
measured. A375 melanoma cells used as a transduction control were routinely 30-50% 
transduced from each transduction. After eight transductions of TALL-104 cells, populations 
transduced with both vectors were between 0.8 and 0.9% fluorescent (data not shown). 
Therefore, approximately 0.1% of the cells were transduced in each attempt TALL-104 is a 
slow growing cell line requiring a minimum of 9x10^ cells/ml to grow and 1.5x10^ cells/ml 
to cryopreserve. Low transduction rates coupled with slow growth has limited the ability to 
select fluorescent TALL-104 cells for further analysis. NK-92 LEL eGFP positive cells have 
been selected using cell sorting and NK-92 LESN cells have been selected in media 
containing 1 mg/ml G418 (Figure IB). 
1CP47 and US11 function in TALL-104 and NK-92 cells. LXSN, LISN, and 
LUSN vectors were transduced into the TALL-104 and NK-92 cell lines as noted above and 
transduced populations were selected in media containing 1 mg/ml G418. Both genes 
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decreased class I MHC cell surface expression in both cell lines. In TALL-104 cells, LISN 
decreased class I MHC expression by 71% and LUSN decreased class I MHC expression by 
52% over non transduced control cells (Figure 2E). LXSN transduced TALL-104 cells 
became contaminated during their expansion and were not able to be tested. It is clear that in 
the LISN transduced population, there are cells that are negative for cell surface class I MHC 
expression as evidenced by the broad dual peak histogram (Figure 2C). In NK-92 cells 
similar result were observed. LISN transduced NK-92 cells had 52% and LUSN had 32% 
less expression of cell surface class I MHC as compared to LXSN transduced controls 
(Figure 3F). Again, the histogram for the LISN transduced NK-92 analysis indicates there is 
an identifiable population of class I MHC negative cells (Figure 3D). Both LISN and LUSN 
function to decrease class I MHC cell surface expression in the TALL-104 and NK-92 
lymphocyte cell lines. 
NK-92 LEL cells transduced with LXSN, LISN, and LUSN vectors. To 
investigate the possibility of transducing NK-92 cells with two retroviral vectors, NK-92 
LEL cells were transduced with the LXSN, LISN, and LUSN vectors. After selection in 
media containing 1 mg/ml G418 for 2 weeks, the populations were analyzed by flow 
cytometry for both eGFP and class I MHC expression. G418 selection did not appear to 
adversely af&ct eGFP expression (Figure 4). LISN and LUSN selected cells had 53% and 
83% less class I MHC cell surface expression as compared to LXSN transduced. Thus, 
transduction using two vectors with two diffèrent selection markers is a viable approach for 
introducing multiple genes into the NK-92 cell line. 
Anti-tumor cytotoxicity is maintained in transduced NK-92 cell lines. To 
determine if decreasing the class I MHC presentation on NK-92 cells negatively impacted 
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their ability to attack tumor cells, the specific cytotoxicity of the transduced NK-92 
populations was tested against a panel of tumor cell targets. The class I MHC positive A375 
melanoma and VA13 fibroblast and the class I MHC negative K562 lymphoblast and HCT15 
adenocarcenoma were chosen as targets. At an effectorztarget ratio of 15:1, in a Eve hour 
cytotoxicity assay, all the transduced NK-92 populations killed the tumor cells at efficiencies 
similar to non transduced NK-92 cells (Figure 5). Therefore, the transduction process, class I 
MHC suppression, Neo* expression, and eGFP expression did not prevent NK-92 cells from 
efficiently killing tumor cells. 
Decreased class I MHC expression in LUSN transduced SQ172 cell line. In a 
separate application of US11 class I MHC suppression, the LUSN vector was used to 
decrease class I MHC expression in the SQ172 cell line. Due to the lack of function of 
ICP47 in murine cell lines, the LISN vector was not used for these experiments [27]. SQ172 
cells were transduced with the LUSN vector and class I MHC cell surface expression was 
determined (Figure 6). Although LUSN transduced SQ172 cells expressed 52% less than 
LXSN transduced, they expressed just 16% less cell surface class I MHC as compared to 
non-transduced. In order to see if these levels of class I MHC reduction had any effect on 
tumor longevity m vhw, cells were injected into haplotype matched outbred mice from the 
same a-gal knockout colony which originally generated die tumor. 
Decreased mouse survival when LUSN transduced SQ172 carcinoma cells are 
injected. Four groups of eight H-2^ haplotype matched 8-12 week old a-gal knockout mice 
were selected. Groups 1 and 2 were injected with 5x10* and 1x10* SQ172 no vector (NV) 
cells (Figure 7). Groups 3 and 4 received 1x10* SQ172 LXSN and SQ172 LUSN cells 
respectively. In both the SQ172 NV control groups and the SQ172 LXSN transduced group, 
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at least 75% of the tumors regressed and the mice survived. In the SQ172 LUSN group, 75% 
of the animals grew tumors large enough where the animals had to be sacrificed according to 
protocol. 
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DISCUSSION 
CTL lysis mediated by class I MHC presented antigens is one of many ways our 
immune system protects us from our potentially dangerous environment. Several factors 
must be considered when designing a useful application for the suppression of this one aspect 
of the immune response. First, the target cells must use class I MHC processing and 
presentation of antigens. In most cases class I MHC presents short peptides generated by 
proteasome degradation of cytoplasmic proteins. Genetic mutations producing altered 
proteins, haplotype mismatched cells, and viral infected cells are all capable of presenting 
antigens to CTL. Second, by decreasing only the class I MHC mediated immune response, 
the immune suppression is likely to be effective only until Ab mediated and other immune 
responses intervene. Cancer treatments involving allogeneic transplant of anti-tumor cells 
require injecting a haplotype mismatched lymphocyte into a patient [6]. Minimizing the 
patient's immime response to these therapeutic lymphocytes would prolong their effective 
duration in the patient Cancer treatments often benefit by stimulating or augmenting a 
patient's immune response to cancer cells and thus general immune suppression is not an 
option. Therapies utilizing TALL-104 and NK-92 cell lines would likely benefit if these cell 
lines were able to avoid the patient's immune detection. 
Lymphocytes are efficient antigen presenting cells that interact with many cells of the 
immune system to stimulate cytokine secretion and induce recruitment and proliferation of 
antigen responsive cells. Although retroviral transduction of lymphocytes is often difficult, 
the ability to select and propagate NK-92 and TALL-104 cells m vifro minimizes this 
obstacle (Figure 1). Both ICP47 and US11 decreased class I MHC expression in NK-92 and 
TALL-104 cells (Figure 2, 3) and the decrease lasted over six months in continuous culture 
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(data not shown). Transduction and selection of NK-92 cells did not decrease the anti-tumor 
activity against a panel of 4 cell lines (Figure 5). Continuing work is underway and focuses 
on sorting populations of class I MHC negative NK-92 and determining the extent of their 
ability to evade host detection m vifro. 
To further improve NK-92 cells, it will be necessary to introduce additional 
therapeutic genes. To demonstrate 2 separate vector transductions into the same NK-92 cells, 
NK-92 LEL cells were transduced with the LXSN, LISN, and LUSN vectors (Figure 4). The 
cells were then selected for in media containing G418 and analyzed for both eGFP and class I 
MHC expression. All the populations maintained their high level of eGFP expression while 
the LISN and LUSN transduced populations displayed decreased cell surface class I MHC. 
The function of both genes indicates transduction of both vectors was successful. 
Incorporating suicide genes such as HSV thymidine kinase may remove the necessity to 
irradiate these cells prior to use in either bone marrow purging or allogeneic transplant [28, 
29]. Such modified cells could be allowed to expand fa vfvo during the treatment and 
eliminated as needed once they are finished or if complications arise. ICP47 and US11 
transduction into the NK-92 cell line already encoding IL2 is another possible improvement 
[30]. Such further refinements of both TALL-104 and NK-92 cells are very promising. 
Using US11 to prolong tumor survival in mouse cancer models is another application 
where short-term suppression of cell surface class I MHC expression may prove useful. One 
way some tumors avoid detection and elimination by host immune response is by decreasing 
or eliminating class I MHC expression [31,32]. Thus, class I MHC down regulation may aid 
in establishing tumor cell lines that grow m vfvo for use as tumor models. The vast majority 
of tumor models are developed in rodents and the lack of function of ICP47 in rodent cells 
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makes US11 the choice for use in this application [33]. SQ172 carcinoma cells injected into 
haplotype matched mice establish tumors infrequently. After injection, growth initiates until 
approximately 7-10 days when the tumors begin to regress [16]. To see if decreasing the 
expression of cell surface antigens on class I MHC would prolong the survival of these 
tumors, SQ172 cells were transduced with LXSN and LUSN retrovirus (Figure 6). LXSN 
transduced SQ172 carcinoma cells show increased cell surface class I MHC expression that 
is often observed and may result from the addition of vector proteins being processed for 
presentation [34]. Compared to SQ172 LXSN cells, SQ172 LUSN cells display 52% less 
cell surface class I MHC however they are display only 16% less class I MHC than SQ172 
NV control cells. In results from preliminary tumor growth experiments, these differences 
corresponded to an increase in tumor growth and mouse mortality (Figure 7). Although these 
results are promising, the many potential factors affecting m vrvo tumor development require 
further testing to directly link the observed tumor growth to inhibition of host CTL response. 
Further experiments on SQ172 LUSN and other tumor cell lines generated from a-gal 
knockout mice for use as tumor models have been postponed while an inbred colony of H-
2^ haplotype mice is being developed. 
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Figure 1. eGFP fluorescence in NK-92 and TALL-104 cells. TALL-104 and NK-92 
were transduced with supematants containing LEL and LESN vectors. NK-92 LEL 
transduced cells were selected using a flow cytometer. NK-92 LESN transduced cells 
were selected for by growth in media containing Img/ml (3418. Fluorescence 
microscopy and flow cytometry results are presented for each sample. A) NK-92 control 
cells. B) NK-92 cells transduced with LEL C) NK-92 cells transduced with LESN. D) 
TALL-104 cells transduced with LEL. 
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Figure 2. Class IMHC down regulation in LISN and LUSN transduced TALL-104 cells. 
TALL-104 cells were transduced with the LISN and LUSN vectors, selected in media 
containing G418, and assayed for cell surface class I MHC expression. A) TALL-104 
no vector (NV) cells labeled with isotype control and a FITC secondary Ab. B) TALL-
104 NV cells labeled with the H58A anti-class I MHC Ab. C) TALL-104 LISN cells 
labeled with anti-class I MHC Ab. D) TALL-104 LUSN cells labeled with anti-class I 
MHC Ab. E) Average class I MHC expression of the 4 cell lines. Although the average 
level of class I MHC expression in TALL-104 LISN cells is 52% as compared to LXSN 
control, there are clearly class I MHC negative cells in the population. 
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Figure 3. Class I MHC down regulation in LISN and LUSN transduced NK-92 cells. 
NK-92 cells were transduced with the LISN and LUSN vectors, selected in media 
containing G418, and assayed for cell surface class I MHC expression. Cell pictures 
were taken at 40X magnification using a GFP fluorescence microscope. A) NK-92 no 
vector (NV) cells labeled with isotype control and a FITC secondary Ab. B) NK-92 NV 
cells labeled with the H58A anti-class I MHC Ab. C) NK-92 LXSN cells labeled with 
anti-class I MHC Ab. D) NK-92 LISN cells labeled with anti-class I MHC Ab. E) NK-
92 LUSN cells labeled with anti-class I MHC Ab. F) Average class I MHC expression 
of the 5 cell lines. Although the average level of class I MHC expression in NK-92 LISN 
cells is 52% as compared to LXSN control, there are clearly class I MHC negative cells 
in the population. 
122 
NK-92 ISOTYPE 
%o" * '» « 'H'MjjU' * * WMWL, 
NK 92 ANTI MHCI 
C. NK 92 LXSN ANTI MHCI 
aw 
E. NK 92 LUSN ANTI MHCI 
E 
1 
il F 
8 , SÏMi: 
280 
200 
180 
100 
D. NK-92 LISN ANTI MHCI 
F. 
152% 132% 
Control NK-92 NV NK42 NK42 
LX8N LISN 
Figure 4. NK-92 LEL/LISN and NK-92 LEL/LUSN dual expression in NK-92 cells. 
NK-92 LEL cells were transduced with supematants containing LISN and LUSN. 
Populations were selected for in media containing G418 and cell surface expression of 
class I MHC was determined. A) Two color flow cytometry of NK-92 LEL cells labeled 
with isotype control primary Ab and R-Phycoerithrin secondary Ab. Increasing class I 
MHC is indicated on the Y axis and increasing eGFP fluorescence is indicated on the X 
axis. B) Two color flow cytometry ofNK-92 LEL cells labeled with anti MHC I Ab. C) 
Two color flow cytometry of NK-92 LEL/LISN cells labeled with anti MHC I Ab. D) 
Two color flow cytometry ofNK-92 LEL/LUSN cells labeled with anti MHC I Ab. E) 
Average fluorescence of the 4 labeled populations. While eGFP fluorescence remains 
high, LISN and LUSN populations show 53% and 83% less cell surface class I MHC. 
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Figure 5. Anti-tumor cytotoxicity maintained in NK-92 transduced cell lines. At a 15:1 
effectortarget ratio in a 5 hour cytotoxicity assay, NK-92 cells maintained between 25-
40% specific cytotoxicity was maintained against a panel of 4 cell lines. A375 melanoma 
and VA13 fibroblast cells are class I MHC positive while K562 and HCT15 cells are 
class I MHC negative. 
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Figure 6. Decreased class I MHC expression in LUSN transduced SQ172 cell line. 
SQ172 cells were transduced with the LXSN and LUSN vectors. Class I MHC 
expression was determined using an anti-class I MHC Ab, fluorescent secondary, and 
flow cytometry. An isotype matched Ab was used to control for non specific labeling 
and mean fluorescence is reported for each population. 
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Figure 7. Decreased mouse survival when challenged with SQ172. SQ172, SQ172 
LXSN, and SQ172 LUSN cells were injected subcutaneously at the doses noted and 
tumor growth was monitored. Animals were euthanized if tumors ulcerated or grew 
beyond 1 cm^. 
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CHAPTERS. GENERAL CONCLUSIONS 
GENERAL CONCLUSIONS 
Therapeutic genes administered to patients often encode proteins with epitopes 
foreign to the patient's immune system. These epitopes are processed and presented at the 
cell surface on class I MHC molecules. Retrovirus mediated ICP47 and US11 expression in 
cells leads to a decrease in cell surface presentation of class I MHC proteins. The decrease in 
cell surface class I MHC expression results in an inhibition of the CTL activity as measured 
by an m cytotoxicity assay. Although both genes function in all the human cell lines 
tested, variability in function between the two genes was noted. Variability of ICP47 
function across the panel of cell lines was also noted. Growth of cells in media containing 
IFNy lessened or negated the class I MHC suppression. Both variable function of ICP47 and 
US11 and cytokine mediated upregualation of class I MHC present obstacles to the use of 
these genes for promoting long-term transgene survival. 
As two independent inhibitors of class I MHC presentation, ICP47 and US 11 are 
outstanding tools to study the mechanisms involved with specific CTL/target interactions. 
The class I MHC nonrestricted TALL-104 cell line kills tumor cells preferentially regardless 
of their haplotype. Target cells transduced with ICP47 and US11 present reduced levels of 
class I MHC and were killed less efficiently by TALL-104 cells. Transduction of the genes 
into class I MHC negative cells had no effect on the ability of TALL-104 cells to kill them. 
Thus, TALL-104 cells can distinguish target cells based on the amount of their cell surface 
class I MHC expression in a nonrestricted fashion. Understanding the mechanism of TALL-
104 cell targeting will aid in designing clinical applications for these cells. 
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TALL-104 and NK-92 are two cytotoxic cell lines that preferentially kill tumor cells 
and are currently in clinical trials for use as an allogeneic transplant to treat cancer. ICP47 
and USl 1 decrease class I MHC expression in both of these cell lines. The transduction and 
selection process does not decrease the ability of NK-92 cells to kill tumor cells. By 
decreasing class I MHC expression in these cells, allogeneic transplants may persist longer in 
patients improving the outcome of this therapy. 
Establishing tumor model systems from primary tumor cells is often difficult 
Immunological barriers can prevent tumor growth when cells are reintroduced into mice. 
The SQ172 cell line failed to establish tumors when injected into mice from the same outbred 
colony where it was generated. US 11 expression decreased cell surface class I MHC 
expression in this cell line. SQ172 cells transduced with the LUSN vector formed tumors 
more often than control vector transduced SQ172 cells. Although further analysis is needed 
to demonstrate an evasion of CTL response, USl 1 reduction of class I MHC expression may 
prove useful in establishing murine tumor models. 
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RECCOMMENDATIONS FOR FUTURE RESEARCH 
ICP47 and US11 have proven useful for improving our understanding of the 
presentation and processing of class I MHC antigens and may improve a variety of m vivo 
therapeutic treatments that are subject to CTL mediated host immune response. To further 
these advances, several lines of investigation look promising. 
Commandeering interferon gamma (IFNy). Genes encoding class I and II MHC 
proteins are regulated by gamma interferon activated sites (GAS) that respond to IFNy [1,2]. 
The signal transduction occurs through the Janus kinase (JAK) signal transducer and 
activator of transcription (STAT) pathway (Figure 1). Many immune responder cells secrete 
IFNy as an initial response when encountering stressed, damaged, or antigen presenting cells. 
IFNy then up regulates class I and H MHC gene expression in the surrounding cells enabling 
recruited lymphocytes to sample intracellular and extracellular antigens present [3,4]. With 
appropriate antigen stimulation, cell proliferation followed by removal of the target cells 
occurs. Proteins encoded by therapeutic transgenes are also subject to this process and 
physiological levels of IFNy can negate ICP47 and US11 suppression (Chapter 2 figure 6, 7). 
One approach that may solve this dilemma is to construct gene transfer vectors with GAS 
sequences regulating the expression of ICP47 and US11. In response to IFNy, the up 
regulation of ICP47 and USl 1 may be able to counteract the up regulation of class I MHC 
genes. 
Characterizing non-classical (class lb) class I MHC molecules. The class I MHC 
is polygenic, polymorphic, and variants inherited from both parents are expressed co-
dominant. The resulting array of class I MHC molecules are categorized into haplotype 
groups based on function and structure. ICP47 and US 11 inhibitors of class I MHC 
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presentation are useful tools to clarify the functions of these proteins. CD1D and HLA-E are 
two class lb MHC molecules with unique functions that require further study. CD1D 
presents glycolipid antigens in a pathway distinct from the classical class I MHC [5, 6]. 
HLA-E presents leader sequences clipped from other class I MHC proteins and knowledge of 
its roles in both transplant rejection and NK regulation continues to expand [7]. Determining 
the function of ICP47 and USl 1 with respect to both of these class I MHC proteins could 
answer questions about TAP involvement, peptide requirement, and sub-cellular localization. 
Quantification of CTL responses. Down regulation of class I MHC presentation by 
ICP47 and USl 1 in TALL 104, NK-92, and SQ172 cells was demonstrated. It will be useful 
confirm a decrease in CTL activity against these target cells. For TALL-104 and NK-92 
cells, this will require m vffro priming of random donor lymphocyte populations followed by 
an ^Cr release assay to measure specific cytotoxicity [8]. A ^Cr release is necessary for 
mixed lymphocyte reactions such as this when both cell lines can act as elector or target. 
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Figure 1. Interferon gamma signal transduction through the JAK STAT signal 
transduction pathway. IFNy binds to cell surface receptors forming dimers. The 
conformational change leads to the phosphorylation of the Janus kinase (JAK) 1 and 2. 
These activated kinases then phosphorylate the signal transducer and activator of 
transcription (STAT) proteins. Phosphorylated STAT proteins are transported into the 
nucleus where they bind to gamma interferon activated sites (GAS) and initiate gene 
transcription. 
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